Ajinomoto Bio-Pharma Services Successfully Develops Highly Functional Ancestral RNA Ligase

Rhea-AI Summary

Ajinomoto Bio-Pharma Services announced a significant breakthrough in developing a new enzyme for double strand oligonucleotide formation, collaborating with the University of Shizuoka. This new artificial RNA ligase shows higher thermostability and superior ligation activity compared to natural alternatives, achieving an 80% yield in synthesizing marketed siRNA drug substances, a significant increase from the 20% yield with the natural RNA ligase. This advancement enables environmentally friendly and efficient oligonucleotide synthesis, paving the way for mass production of high-purity nucleic acid drugs. These findings were published in the journal 'Applied and Environmental Microbiology.'

Positive

• Achieved 80% yield in oligonucleotide synthesis, significantly higher than the 20% yield from natural RNA ligase.
• New enzyme development enhances productivity and environmental safety in nucleic acid synthesis.

Negative

• None.

TOKYO, Feb. 22, 2023 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce the development of a new enzyme for double strand oligonucleotide formation with high productivity.

In collaboration with researchers from the University of Shizuoka, Aji Bio-Pharma succeeded in developing a highly functional artificial RNA ligase using the ancestral design method. It was found that this artificial RNA ligase has higher thermostability than natural RNA ligase as well as superior ligation activity for RNA fragments containing xenonucleic acid.

When using the natural RNA ligase for RNA fragments (including xenonucleic acid) as reaction substrates to synthesize a marketed siRNA drug substance, the yield was only 20% after 24 hours of reaction. In contrast, when using the highly functional artificial RNA ligase, the reaction yield improved to 80% under the same conditions, confirming that it has properties suitable for enzymatic synthesis of nucleic acid medicines. This approach attains more productive and environmentally safe oligonucleotide synthesis when compared to the conventional method.

 "We are excited to provide new research to our partners and support them in their efforts to supply lifesaving therapeutics," said Yusuke Hagiwara, Senior Researcher, Ajinomoto Bioscience & Fine Chemicals Research Laboratories. "This discovery for siRNA is a great example of Aji Bio-Pharma continuing to provide reliable and innovative solutions to our clients."

The RNA fragments used as reaction substrates can be produced by not only conventional solid phase synthesis, but also by Ajinomoto Co.'s AJIPHASE^® technology, especially in large quantities and with high purity. This achievement is expected to be applied as one of the technologies that enables the mass production of nucleic acid drugs with high efficiency and high purity. This result was presented in the journal "Applied and Environmental Microbiology" published by the American Society for Microbiology.

About Ajinomoto Co. and Ajinomoto Bio-Pharma Services

Based on the corporate message "Eat Well, Live Well.", Ajinomoto Co., Inc. has been scientifically pursuing the possibilities of amino acids to aim for future growth by creating new value through sustainable and innovative solutions for communities and society. For additional information about Ajinomoto Co. (TYO: 2802), please visit www.ajinomoto.com.

As its pharmaceutical arm, Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization (CDMO) with sites in Belgium, United States, Japan, and India, providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small through large molecule APIs and intermediates. For more information about Ajinomoto Bio-Pharma Services, please visit www.AjiBio-Pharma.com.

In addition, Ajinomoto Co. and Ajinomoto Bio-Pharma Services offer a broad range of innovative platform technologies and capabilities for pre-clinical and pilot programs to commercial quantities, including AJIPHASE^® oligonucleotide manufacturing technology, CORYNEX^® and TALAMAX^® protein expression systems, AJICAP^® site-specific conjugation and linker technologies for ADCs, and continuous flow manufacturing. For additional information on the platform technologies, please visit https://ajibio-pharma.ajinomoto.com/.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ajinomoto-bio-pharma-services-successfully-develops-highly-functional-ancestral-rna-ligase-301752133.html

SOURCE Ajinomoto Bio-Pharma Services

FAQ

What breakthrough did Ajinomoto Bio-Pharma Services achieve in February 2023?

Ajinomoto Bio-Pharma Services developed a new artificial RNA ligase that improves the yield of oligonucleotide synthesis from 20% to 80%.

How does the new RNA ligase compare to natural RNA ligase?

The new RNA ligase has higher thermostability and superior ligation activity, making it more effective for synthesizing nucleic acid medicines.

What is the significance of this development for the nucleic acid drug industry?

This new technology allows for more productive and environmentally safe oligonucleotide synthesis, enabling mass production of high-purity nucleic acid drugs.

Where was the research on the new RNA ligase published?

The findings were published in the journal 'Applied and Environmental Microbiology.'